[{"id":"7731b3b2-049a-4507-9d5f-a1c0e3590901","acronym":"","url":"https://clinicaltrials.gov/study/NCT05744739","created_at":"2023-10-18T17:12:49.031Z","updated_at":"2024-07-02T16:35:06.324Z","phase":"Phase 1","brief_title":"Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05744739","lead_sponsor":"Northwestern University","biomarkers":" MCL1","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tomivosertib (eFT508)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/29/2023","start_date":" 09/29/2023","primary_txt":" Primary completion: 04/23/2029","primary_completion_date":" 04/23/2029","study_txt":" Completion: 04/23/2030","study_completion_date":" 04/23/2030","last_update_posted":"2024-05-02"},{"id":"0304156e-9a2f-42b0-9354-208fb163b3bb","acronym":"KICKSTART","url":"https://clinicaltrials.gov/study/NCT04622007","created_at":"2021-01-19T20:34:40.359Z","updated_at":"2024-07-02T16:35:06.762Z","phase":"Phase 2","brief_title":"Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)","source_id_and_acronym":"NCT04622007 - KICKSTART","lead_sponsor":"Effector Therapeutics","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • tomivosertib (eFT508)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/02/2021","start_date":" 06/02/2021","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 12/09/2024","study_completion_date":" 12/09/2024","last_update_posted":"2024-04-30"},{"id":"180f1f85-4b2d-4469-b365-3d308e1eecf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04261218","created_at":"2021-01-18T20:42:27.035Z","updated_at":"2024-07-02T16:36:07.059Z","phase":"Phase 1","brief_title":"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer","source_id_and_acronym":"NCT04261218","lead_sponsor":"Translational Research in Oncology","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • tomivosertib (eFT508)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 07/04/2022","primary_completion_date":" 07/04/2022","study_txt":" Completion: 07/04/2022","study_completion_date":" 07/04/2022","last_update_posted":"2022-07-20"}]